ABSTRACT
BACKGROUND: Teledermatology (TD) has emerged as a critical way of delivering care remotely in the COVID-19 pandemic. OBJECTIVE: We conducted a systematic review to assess how TD has been implemented worldwide. METHODS: We searched PubMed, Scopus, Embase, Web of Science, and Google Scholar for articles on the use of TD for patient care, written in English and published from December 1, 2019, to October 15, 2020. RESULTS: Twenty-seven studies were included, involving 16,981 patients. There was significant uptake of TD during the pandemic. Synchronous TD appeared to be more commonly implemented than asynchronous TD. Common ambulatory dermatoses such as acne or eczema were reported to be more amenable to TD assessment and management. TD also appeared to be useful for the diagnosis of cutaneous involvement of COVID-19 infection and follow-up of stable oncodermatology cases. LIMITATIONS: A pooled analysis of all relevant outcomes was not always possible due to the heterogeneity in the methodologies of included studies. CONCLUSION: TD is a useful and convenient tool for the management of common ambulatory dermatoses in the COVID-19 pandemic.
ABSTRACT
In conjunction with BMJ Case Reports, DTB will feature occasional drug-related cases that are likely to be of interest to readers. These will include cases that involve recently marketed drugs for which there is limited knowledge of adverse effects and cases that highlight unusual reactions to drugs that have been marketed for several years.
ABSTRACT
We report the experience of reversing dabigatran prior to administering systemic thrombolysis for acute ischaemic cerebellar stroke, which was well tolerated with no haemorrhagic complications after thrombolysis. Given the increasingly common use of dabigatran for atrial fibrillation, the use of idarucizumab to reverse of dabigatran is a novel treatment that should be considered as an important adjunct to facilitate thrombolysis for ischaemic strokes and minimise haemorrhagic complications.
Subject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Brain Ischemia/drug therapy , Dabigatran/adverse effects , Stroke/drug therapy , Thrombolytic Therapy/adverse effects , Aged , Brain Ischemia/diagnostic imaging , Brain Ischemia/pathology , Humans , Male , Stroke/diagnostic imaging , Stroke/pathology , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
Epidermolysis bullosa pruriginosa (EB-Pr) is an unusual variant of dystrophic EB. Potential genetic disease modifiers and metabolic factors have been investigated, but thus far no specific insight into this phenotype has emerged. We report an in-depth description of three patients diagnosed as having EB-Pr in whom this particular phenotype developed after scabies infestation and dramatically improved after full treatment. This short communication suggests that scabies infestation could be one of the important triggering factors for the development of the EB-Pr phenotype.
